Market Overview

Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement

Share:

Mizuho Securities downgraded Cubist Pharmaceuticals Inc (NASDAQ: CBST) Tuesday from Buy to Neutral and raised its price target from $97 to $102.

Analyst Mario Corso noted that after the "market close [Monday] 4 of 5 Cubicin patents were invalidated via court decision, making generics possible in mid-2016, we do not expect this to derail the [Merck & Co., Inc. (NYSE: MRK)] transaction given that this likelihood was considered in the offer, although not excluding the possibility that terms could be altered.”

“Merck announced it is acquiring CBST for $102/share in cash, valuing the company at $8.4bn or $9.5bn including $1.1bn in net debt. MRK is interested in revenue growth opportunities in the acute care/hospital, as well as adding to its pipeline of antibacterial agents that can be leveraged on a worldwide basis,” according to Corso.

The analyst note concluded that “if we genercize Cubicin in June 2016 (which notably isn't the worse case scenario, it could have been immediate generics if all patents were invalidated), it reduces our DCF valuation by ~$10, as generics were previously set to begin mid-2018.”

Cubist Pharmaceuticals Inc recently traded at $96.29, down 4.28 percent.

Merck & Co., Inc. recently traded at $58.89, down 4.84 percent.

Latest Ratings for CBST

DateFirmActionFromTo
Dec 2014UBSDowngradesBuyNeutral
Dec 2014OppenheimerDowngradesOutperformMarket Perform
Dec 2014MizuhoDowngradesBuyNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

 

Related Articles (CBST)

View Comments and Join the Discussion!

Posted-In: Mario Corso Mizuho SecuritiesAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
WINGPiper SandlerMaintains158.0
CMGPiper SandlerMaintains1,450.0
COSTDeutsche BankMaintains298.0
CWXCanaccord GenuityUpgrades4.0
LHCGSunTrust Robinson HumphreyMaintains220.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com